• 1
    Hollingsworth JM, Miller DC, Daignault S, Hollenbeck BK. Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst. 2006; 98: 1331-1334.
  • 2
    Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006; 175: 425-431.
  • 3
    Klatte T, Patard JJ, de Martino M, et al. Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol. 2008; 179: 1719-1726.
  • 4
    Volpe A, Kachura JR, Geddie WR, et al. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol. 2007; 178: 379-386.
  • 5
    Patard JJ, Fergelot P, Karakiewicz PI, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma (RCC). Int J Cancer. 2008; 123: 395-400.
  • 6
    Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst. 2002; 94: 1569-1575.
  • 7
    Klatte T, Rao PN, de Martino M, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol. 2009; 27: 746-753.
  • 8
    Presti JC, Wilhelm M, Reuter V, Russo P, Motzer R, Waldman F. Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol. 2002; 167: 1464-1468.
  • 9
    Schullerus D, Herbers J, Chudek J, Kanamaru H, Kovacs G. Loss of heterozygosity at chromosomes 8p, 9p, and 14q is associated with stage and grade of non-papillary renal cell carcinomas. J Pathol. 1997; 183: 151-155.
  • 10
    Brunelli M, Eccher A, Gobbo S, et al. Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol. 2008; 21: 1-6.
  • 11
    Cairns P, Tokino K, Eby Y, Sidransky D. Localization of tumor suppressor loci on chromosome 9 in primary human renal cell carcinomas. Cancer Res. 1995; 55: 224-227.
  • 12
    Jaeger E. Waldmann F, Roydasgupta R, et al. Array-based comparative genomic hybridization (CGH) identifies chromosomal imbalances between interleukin-2 complete and non-responders [abstract]. J Clin Oncol. 2008; 26(May 20 suppl). Abstract 5043.
  • 13
    Klatte T, Lam JS, Shuch B, Belldegrun AS, Pantuck AJ. Surveillance for renal cell carcinoma: why and how? When and how often? Urol Oncol. 2008; 26: 550-554.
  • 14
    Kinkle DA, Crispen PL, Chen DYT, Greenberg RE, Uzzo RG. Enhancing renal masses with zero net growth during active surveillance. J Urol. 2007; 177: 849-854.
  • 15
    Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003; 9: 802-811.
  • 16
    Atkins M, Regan M, McDermott D, et al. Carbonic anhydrase IX expression predicts outcome of interleukin-2 therapy for renal cancer. Clin Cancer Res. 2005; 11: 3714-3721.